IASO 782
Alternative Names: IASO-782Latest Information Update: 28 Aug 2023
At a glance
- Originator Nanjing IASO Biotechnology
- Class Antianaemics; Antihaemorrhagics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemolytic anaemia; Thrombocytopenia